サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1345522

ワクチンアジュバントの世界市場：製品タイプ別、投与経路別、疾患タイプ別、タイプ別-2028年までの予測

Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine, Veterinary vaccine) - Global Forecast to 2028
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 231 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ワクチンアジュバントの世界市場：製品タイプ別、投与経路別、疾患タイプ別、タイプ別-2028年までの予測
出版日: 2023年09月04日
発行: MarketsandMarkets
ページ情報: 英文 231 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のワクチンアジュバントの市場規模は、2023年の8億米ドルから2028年には12億米ドルに達すると予測され、予測期間中のCAGRは6.9%と見込まれています。

感染症の流行増加、臨床試験中のワクチン数の増加、予防接種プログラムへの注目の高まりなどの要因が、市場成長にプラスの影響を与えそうです。

製品に基づき、世界のワクチンアジュバント市場は病原体成分、アジュバントエマルジョン、微粒子アジュバント、サポニンベースのアジュバント、その他のアジュバントに区分されます。2022年にはアジュバント乳剤セグメントが市場で圧倒的なシェアを占めました。COVID-19およびその他の感染症におけるアジュバント乳剤の広範な使用、および伝染病の有病率の上昇は、市場の成長にプラスの影響を与えるとみられています。

疾患タイプ別では、ワクチンアジュバント市場は感染症、癌、その他の疾患に区分されます。2022年には、感染症分野がワクチンアジュバント市場で最大のシェアを占めました。感染症の蔓延の増加や、インフルエンザなどの感染症に対する新しいアジュバントワクチンの需要の高まりなど、さまざまな要因から、同セグメントが市場で圧倒的なシェアを占めています。

ワクチンアジュバント市場は、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカに区分されます。アジア太平洋は予測期間中に高いCAGRで成長すると予測されています。ワクチン開発に従事する有力企業が存在するため、中国、インド、日本からのワクチンアジュバント需要が増加しており、アジア太平洋地域の市場開拓を支えています。さらに、癌罹患率の上昇、ワクチン開発と予防接種に対する政府の取り組みが、市場成長にプラスの影響を与えると予想される要素の一部です。

当レポートでは、世界のワクチンアジュバント市場について調査し、製品タイプ別、投与経路別、疾患タイプ別、タイプ別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客のビジネスに影響を与える動向/混乱
  • 価格分析
  • 技術分析
  • バリューチェーン分析
  • エコシステム分析
  • 2023年～2024年の主な会議とイベント
  • 規制分析
  • ポーターのファイブフォース分析
  • 主要な利害関係者と購入基準

第6章 ワクチンアジュバント市場、製品別

  • イントロダクション
  • アジュバントエマルション
  • 病原体の成分
  • サポニンベースのアジュバント
  • その他

第7章 ワクチンアジュバント市場、投与経路別

  • イントロダクション
  • 筋肉内
  • 皮下
  • その他

第8章 ワクチンアジュバント市場、疾患タイプ別

  • イントロダクション
  • 感染症
  • 癌
  • その他

第9章 ワクチンアジュバント市場、用途別

  • イントロダクション
  • 研究
  • 商業用途

第10章 ワクチンアジュバント市場、タイプ別

  • イントロダクション
  • ヒト用ワクチンアジュバント
  • 動物用ワクチンアジュバント

第11章 ワクチンアジュバント市場、地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • イントロダクション
  • 主要参入企業が採用した戦略
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 新興企業/中小企業の評価マトリックス
  • 新興企業/中小企業参入企業の競合ベンチマーキング
  • 競合シナリオと動向

第13章 企業プロファイル

  • 主要な市場参入企業
    • DYNAVAX TECHNOLOGIES
    • CRODA INTERNATIONAL PLC
    • GSK PLC
    • SEPPIC（A SUBSIDIARY OF AIR LIQUIDE GROUP）
    • NOVAVAX
    • SPI PHARMA（A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC）
    • AGENUS INC.
    • PHIBRO ANIMAL HEALTH CORPORATION
    • AURORIUM（FORMERLY VERTELLUS）
    • MERCK KGAA
    • VAXINE PTY LTD.
    • HAWAII BIOTECH INC.
    • CSL LIMITED
    • OZ BIOSCIENCES
    • INVIVOGEN
    • ALLERGY THERAPEUTICS
    • EUBIOLOGICS CO., LTD.
    • PACIFIC GENETECH LIMITED
    • RIBOXX GMBH
    • CAPTIVATE PHARMACEUTICALS LLC
  • その他の企業
    • CREATIVE DIAGNOSTICS
    • LITEVAX B.V.
    • MUKTA INDUSTRIES
    • ONCOVIR, INC.
    • TITERMAX USA, INC.

第14章 付録

目次
Product Code: BT 4378

The global vaccine adjuvants market size is projected to reach USD 1.2 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.9% during the forecast period. Factors such as as the rising prevalence of infectious diseases, increasing number of vaccines under clinical trials, and increasing focus on immunization programs are likely to have positive impact on the market growth.

"The adjuvant emulsions segment held the dominant share in the vaccine adjuvants market"

Based on product, the global vaccine adjuvants market is segmented into pathogen component, adjuvant emulsions, particulate adjuvants, saponin-based adjuvants and other adjuvants. The adjuvant emulsions segment held a dominant share in the market in 2022. Extensive use of adjuvant emulsions in COVID-19 & other infectious diseases and the rising prevalence of contagious diseases are likely to have positive impact on the growth of the market.

"infectious disease segment accounted for the largest share of the disease type segment in 2022."

Based on disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer and other diseases. In 2022, the infectious disease segment accounted for the largest share of the vaccine adjuvants market. The segment held the dominant share in the market owing to various factors such as increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines for infectious diseases such as influenza.

"Asia Pacific region is likely to grow at a faster pace."

The vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The increasing demand for vaccine adjuvants from China, India, and Japan due to presence of prominent players engaged in vaccine development, supports market growth in the Asia Pacific. Furthermore rising cancer incidence and government initiatives for vaccine development and immunization are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

  • Dynavax Technologies (US)
  • Croda International plc (UK)
  • GSK plc (UK)
  • Seppic (France)
  • Novavax (US)
  • SPI pharma ( subsidiary of Associated British Foods plc ) (UK)
  • Agenus Inc. (US)
  • Phibro Animal Health Corporation (US)
  • Aurorium (Vertellus) (US)
  • Merck KGaA (Germany)
  • Vaxine Pty Ltd. (Australia)
  • Hawaii Biotech Inc. (US)
  • CSL Limited (Australia)
  • OZ Biosciences (US)
  • InvivoGen (US)
  • Allergy Therapeutics (UK)
  • EuBiologics Co., Ltd. (South Korea)
  • Pacific GeneTech Limited (US)
  • Riboxx GmbH (Germany)
  • CaPtivate Pharmaceuticals LLC (US)
  • Creative Diagnostics (US)
  • LiteVax BV (Netherlands)
  • Mukta Industries (India)
  • Oncovir, Inc. (US)
  • TiterMax USA, Inc. (US).

Research Coverage:

This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising prevalence of infectious diseases, increasing collaborations and partnerships among market players for adjuvanted vaccines development, Growing product pipeline, Growing focus on immunization programs), restraints ( Side effects and high toxicity of adjuvants), opportunities (Growing funding for vaccines and increasing infectious disease research activities, development of plant-based vaccine adjuvants) and challenges (Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing) are influencing the growth of vaccine adjuvants market.
  • Product Development/Innovation: Detailed insights on newly launched products of the vaccine adjuvants market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the vaccine adjuvants market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccine adjuvants market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Dynavax Technologies (US), Croda International plc (UK), GSK plc (UK), Seppic (France) , Novavax (US), SPI pharma (US), Agenus Inc. (US), Phibro Animal Health Corporation (US) and among others in the vaccine adjuvants market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
  • 1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 PRIMARY RESEARCH
    • FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS
    • 2.1.2 SECONDARY DATA
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, ROUTE OF ADMINISTRATION, DISEASE TYPE, APPLICATION, TYPE, AND REGION)
    • FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS
    • FIGURE 7 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS
    • FIGURE 8 VACCINE ADJUVANTS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 10 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 VACCINE ADJUVANTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET

4 PREMIUM INSIGHTS

  • 4.1 VACCINE ADJUVANTS MARKET OVERVIEW
    • FIGURE 16 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2022)
    • FIGURE 17 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINE ADJUVANTS MARKET IN 2022
  • 4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2023 VS. 2028
    • FIGURE 18 ADJUVANT EMULSIONS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028
  • 4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of infectious diseases
      • 5.2.1.2 Increasing collaborations and partnerships among market players for adjuvanted vaccine development
      • 5.2.1.3 Growing product pipeline
    • FIGURE 21 PIPELINE OF VACCINE ADJUVANTS
      • 5.2.1.4 Growing focus on immunization programs
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Side effects and toxicity of adjuvants
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing funding for vaccines and increasing infectious disease research activities
    • TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2019-2023 (USD MILLION)
      • 5.2.3.2 Development of plant-based vaccine adjuvants
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Concerns regarding animal-sourced vaccine adjuvants and shark fishing
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 22 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS
    • TABLE 4 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (TOP 5)
    • 5.4.2 AVERAGE SELLING PRICE, BY PRODUCT TYPE
    • TABLE 5 AVERAGE SELLING PRICE OF ADJUVANT EMULSIONS
    • TABLE 6 AVERAGE SELLING PRICE OF PARTICULATE ADJUVANTS
    • TABLE 7 AVERAGE SELLING PRICE OF SAPONIN-BASED ADJUVANTS
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 24 ECOSYSTEM ANALYSIS
    • TABLE 8 SUPPLY CHAIN ECOSYSTEM
  • 5.8 KEY CONFERENCES & EVENTS IN 2023-2024
    • TABLE 9 VACCINE ADJUVANTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY LANDSCAPE FOR VACCINE ADJUVANTS
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 15 VACCINE ADJUVANTS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 THREAT OF NEW ENTRANTS
    • 5.10.2 THREAT OF SUBSTITUTES
    • 5.10.3 BARGAINING POWER OF SUPPLIERS
    • 5.10.4 BARGAINING POWER OF BUYERS
    • 5.10.5 DEGREE OF COMPETITION
    • FIGURE 25 PATENT APPLICATIONS FOR VACCINE ADJUVANTS, AUGUST 2013-AUGUST 2023
    • TABLE 16 VACCINE ADJUVANTS MARKET: INDICATIVE LIST OF PATENTS
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINE ADJUVANTS
    • 5.11.2 BUYING CRITERIA FOR VACCINE ADJUVANT PRODUCTS
    • FIGURE 27 KEY BUYING CRITERIA FOR END USERS

6 VACCINE ADJUVANTS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 17 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 ADJUVANT EMULSIONS
    • 6.2.1 EXTENSIVE USE OF ADJUVANT EMULSIONS IN HUMAN VACCINES TO DRIVE GROWTH
    • TABLE 18 ADJUVANT EMULSIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 19 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 PATHOGEN COMPONENTS
    • 6.3.1 INCREASING NUMBER OF PROMINENT PLAYERS OFFERING BACTERIA-DERIVED ADJUVANTS TO DRIVE GROWTH
    • TABLE 22 PATHOGEN COMPONENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 23 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 SAPONIN-BASED ADJUVANTS
    • 6.4.1 INCREASING USE OF SAPONIN-BASED ADJUVANTS TO SUPPORT MARKET GROWTH
    • TABLE 26 SAPONIN-BASED ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 27 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 PARTICULATE ADJUVANTS
    • 6.5.1 GROWING DEMAND FOR MINERAL-BASED ADJUVANTS TO BOOST MARKET
    • TABLE 30 PARTICULATE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 31 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.6 OTHER ADJUVANTS
    • TABLE 34 OTHER VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1 INTRODUCTION
    • TABLE 38 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
  • 7.2 INTRAMUSCULAR
    • 7.2.1 BETTER ABSORPTION RATE ASSOCIATED WITH INTRAMUSCULAR ADMINISTRATION TO DRIVE MARKET GROWTH
    • TABLE 39 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION
    • TABLE 40 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 42 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 SUBCUTANEOUS
    • 7.3.1 FREQUENT USE OF SUBCUTANEOUS ROUTE OF ADMINISTRATION TO BOOST MARKET
    • TABLE 44 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
    • TABLE 45 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 46 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 OTHER ROUTES OF ADMINISTRATION
    • TABLE 49 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021-2028 (USD MILLION)

8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE

  • 8.1 INTRODUCTION
    • TABLE 53 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    • TABLE 54 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 55 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 CANCER
    • 8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH
    • TABLE 58 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 59 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 60 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER DISEASES
    • TABLE 62 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 63 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)

9 VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 66 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 9.2 RESEARCH APPLICATIONS
    • 9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET
    • TABLE 67 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 68 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 COMMERCIAL APPLICATIONS
    • 9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH
    • TABLE 71 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 72 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

10 VACCINE ADJUVANTS MARKET, BY TYPE

  • 10.1 INTRODUCTION
    • TABLE 75 VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 10.2 HUMAN VACCINE ADJUVANTS
    • 10.2.1 INCREASING PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS TO AID MARKET GROWTH
    • TABLE 76 HUMAN VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 77 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 78 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 VETERINARY VACCINE ADJUVANTS
    • 10.3.1 INCREASING USE OF ADJUVANTED VACCINES AS PREVENTIVE CARE IN ANIMAL HEALTH TO DRIVE MARKET
    • TABLE 80 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 81 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

11 VACCINE ADJUVANTS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 84 VACCINE ADJUVANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT
    • TABLE 85 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 87 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 88 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 90 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.2.1 US
      • 11.2.1.1 US to dominate North American market during forecast period
    • TABLE 91 US: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 92 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 93 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 US: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 95 US: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Increasing government funding for vaccine research to drive market growth in Canada
    • TABLE 96 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 97 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 98 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 99 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 100 CANADA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.2.3 NORTH AMERICA: RECESSION IMPACT
  • 11.3 EUROPE
    • TABLE 101 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 102 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 103 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 104 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 105 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 106 EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Increasing investments by various key players to drive market
    • TABLE 107 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 108 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 109 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 111 GERMANY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.2 UK
      • 11.3.2.1 Rising investments in vaccine development to boost market growth
    • TABLE 112 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 113 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 114 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 115 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 116 UK: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.3 FRANCE
      • 11.3.3.1 Growing focus on new vaccine development to drive market growth
    • TABLE 117 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 118 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 119 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 121 FRANCE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growth in life science research to boost market
    • TABLE 122 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 123 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 124 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 125 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 126 ITALY: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increasing investments in vaccine development by government and private organizations to support market
    • TABLE 127 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 128 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 129 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 130 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 131 SPAIN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.6 REST OF EUROPE
    • TABLE 132 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 133 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 134 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 135 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 136 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.3.7 EUROPE: RECESSION IMPACT
  • 11.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT
    • TABLE 137 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.4.1 CHINA
      • 11.4.1.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
    • TABLE 143 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 144 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 145 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 147 CHINA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.4.2 JAPAN
      • 11.4.2.1 Government initiatives to boost market
    • TABLE 148 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 149 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 150 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 151 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 152 JAPAN: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Growth of biotechnology sector to support market
    • TABLE 153 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 154 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 155 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 156 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 157 INDIA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.4.4 REST OF ASIA PACIFIC
    • TABLE 158 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 159 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 160 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 162 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • 11.4.5 ASIA PACIFIC: RECESSION IMPACT
  • 11.5 LATIN AMERICA
    • 11.5.1 GROWING PHARMACEUTICAL & BIOTECHNOLOGY RESEARCH TO DRIVE MARKET GROWTH
    • 11.5.2 LATIN AMERICA: RECESSION IMPACT
    • TABLE 163 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 164 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 165 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 167 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO SUPPORT MARKET GROWTH
    • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 168 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 169 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
    • TABLE 170 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 172 MIDDLE EAST & AFRICA: VACCINE ADJUVANTS MARKET, BY TYPE, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 30 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS
    • FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 12.4 MARKET SHARE ANALYSIS
    • FIGURE 32 VACCINE ADJUVANTS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
    • TABLE 173 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
    • 12.5.5 COMPANY FOOTPRINT
      • 12.5.5.1 Product footprint of top 25 companies
    • TABLE 174 VACCINE ADJUVANTS MARKET: COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
    • 12.5.6 REGIONAL FOOTPRINT OF TOP 25 COMPANIES
    • TABLE 175 VACCINE ADJUVANTS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 34 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
  • 12.7 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 176 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET
    • TABLE 177 VACCINE ADJUVANTS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS
  • 12.8 COMPETITIVE SCENARIO AND TRENDS
    • 12.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 178 VACCINE ADJUVANTS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JULY 2023
    • 12.8.2 DEALS
    • TABLE 179 VACCINE ADJUVANTS MARKET: DEALS, JANUARY 2021-JULY 2023
    • 12.8.3 OTHER DEVELOPMENTS
    • TABLE 180 VACCINE ADJUVANTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2023

13 COMPANY PROFILES

  • (Business overview, Products offered, Recent developments & MnM View)**
  • 13.1 KEY MARKET PLAYERS
    • 13.1.1 DYNAVAX TECHNOLOGIES
    • TABLE 181 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2022)
    • 13.1.2 CRODA INTERNATIONAL PLC
    • TABLE 182 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW
    • FIGURE 36 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2022)
    • 13.1.3 GSK PLC
    • TABLE 183 GSK PLC: BUSINESS OVERVIEW
    • FIGURE 37 GSK PLC: COMPANY SNAPSHOT (2022)
    • 13.1.4 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP)
    • TABLE 184 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): BUSINESS OVERVIEW
    • FIGURE 38 SEPPIC (A SUBSIDIARY OF AIR LIQUIDE GROUP): COMPANY SNAPSHOT (2022)
    • 13.1.5 NOVAVAX
    • TABLE 185 NOVAVAX: BUSINESS OVERVIEW
    • FIGURE 39 NOVAVAX: COMPANY SNAPSHOT (2022)
    • 13.1.6 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC)
    • TABLE 186 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): BUSINESS OVERVIEW
    • FIGURE 40 SPI PHARMA (A SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC): COMPANY SNAPSHOT (2022)
    • 13.1.7 AGENUS INC.
    • TABLE 187 AGENUS INC.: BUSINESS OVERVIEW
    • FIGURE 41 AGENUS INC.: COMPANY SNAPSHOT (2022)
    • 13.1.8 PHIBRO ANIMAL HEALTH CORPORATION
    • TABLE 188 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW
    • FIGURE 42 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2022)
    • 13.1.9 AURORIUM (FORMERLY VERTELLUS)
    • TABLE 189 AURORIUM (FORMERLY VERTELLUS): BUSINESS OVERVIEW
    • 13.1.10 MERCK KGAA
    • TABLE 190 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 13.1.11 VAXINE PTY LTD.
    • TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW
    • 13.1.12 HAWAII BIOTECH INC.
    • TABLE 192 HAWAII BIOTECH INC.: BUSINESS OVERVIEW
    • 13.1.13 CSL LIMITED
    • TABLE 193 CSL LIMITED: BUSINESS OVERVIEW
    • FIGURE 44 CSL LIMITED: COMPANY SNAPSHOT (2022)
    • 13.1.14 OZ BIOSCIENCES
    • TABLE 194 OZ BIOSCIENCES: BUSINESS OVERVIEW
    • 13.1.15 INVIVOGEN
    • TABLE 195 INVIVOGEN: BUSINESS OVERVIEW
    • 13.1.16 ALLERGY THERAPEUTICS
    • TABLE 196 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW
    • FIGURE 45 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2022)
    • 13.1.17 EUBIOLOGICS CO., LTD.
    • TABLE 197 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW
    • 13.1.18 PACIFIC GENETECH LIMITED
    • TABLE 198 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW
    • 13.1.19 RIBOXX GMBH
    • TABLE 199 RIBOXX GMBH: BUSINESS OVERVIEW
    • 13.1.20 CAPTIVATE PHARMACEUTICALS LLC
    • TABLE 200 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW
  • 13.2 OTHER PLAYERS
    • 13.2.1 CREATIVE DIAGNOSTICS
    • 13.2.2 LITEVAX B.V.
    • 13.2.3 MUKTA INDUSTRIES
    • 13.2.4 ONCOVIR, INC.
    • 13.2.5 TITERMAX USA, INC.
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS